GlaxoSmithKline Pakistan's total inventories for the quarter that ended in Mar. 2026 was ₨13,212 Mil. GlaxoSmithKline Pakistan's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was ₨13,140 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. GlaxoSmithKline Pakistan's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ₨3.83.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
GlaxoSmithKline Pakistan's Days Inventory for the
three
months ended in Mar. 2026 was 112.64.
Inventory Turnover measures how fast the company turns over its inventory within a year.
GlaxoSmithKline Pakistan's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.81.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
GlaxoSmithKline Pakistan's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.77.
GlaxoSmithKline Pakistan (KAR:GLAXO) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
GlaxoSmithKline Pakistan's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
GlaxoSmithKline Pakistan's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
GlaxoSmithKline Pakistan Total Inventories Related Terms
GlaxoSmithKline Pakistan Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pakistan Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of ₨13,212 Mil mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Total Inventories of ₨13,212 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for GlaxoSmithKline Pakistan and its competitors.
Is GlaxoSmithKline Pakistan's Total Inventories too high?
GlaxoSmithKline Pakistan's current Total Inventories is ₨13,212 Mil. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Total Inventories compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's Total Inventories of ₨13,212 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for GlaxoSmithKline Pakistan and its competitors. GlaxoSmithKline Pakistan's current Total Inventories is ₨13,212 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current Total Inventories is ₨13,212 Mil. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Total Inventories is ₨13,212 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
Total Inventories: ₨13,212 Mil
GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
